Medical Affairs’ Role in Patient Engagement: Collaboration with Internal and External Stakeholders and Activities along the Patient Journey: Best Practice Summary

STUDY OVERVIEW
BENCHMARK CLASS
SPECIAL OFFER

Non-members: Click here to review a complimentary excerpt from "Medical Affairs' Role in Patient Engagement: Collaboration with Internal and External Stakeholders and Activities along the Patient Journey"

STUDY OVERVIEW

With the shift in the last decade from a support function to an independent role, Medical Affairs groups in the pharmaceutical industry are now playing a bigger role in companies’ patient engagement programs. That means pharma companies with Medical Affairs groups that have evolved into leadership roles are working with both internal and external stakeholders involved in patient engagement activities.

To inform Medical Affairs' efforts on working with internal and external stakeholders regarding patient engagement activities, Best Practices, LLC has published a study examining which internal and external stakeholders are best to work with on this issue. In addition, the study highlights what patient engagement activities/strategies work best for each group of stakeholders. The research also includes chapters on what patient engagement activities Medical Affairs uses along the patient journey and participants' insights into lessons learned and pitfalls.

KEY TOPICS

Collaboration with Internal and External Groups
Role in the Patient Journey
Voices from the Industry on Lessons Learned

KEY METRICS

Involvement level of specific Medical Affairs functions in patient engagement activities
Frequency of collaboration with internal groups on patient engagement activities
Frequency of collaboration with external groups on patient engagement activities
Most effective activities for collaborating with internal groups regarding patient engagement
Most effective activities for collaborating with external groups regarding patient engagement
Effectiveness of patient engagement activities for supporting patients at the early stage of their disease
Effectiveness of patient engagement activities for supporting patients at the late stage of their disease

METHODOLOGY

Best Practices, LLC engaged 39 leaders from 29 biopharmaceutical companies through a benchmarking survey.

Industries Profiled:
Pharmaceutical; Biopharmaceutical; Biotech; Manufacturing; Consumer Products; Diagnostic; Medical Device; Chemical; Health Care

Companies Profiled:
Abbvie; Clovis Oncology; Actelion; TG Therapeutics; Alkermes; Vifor Pharma; AstraZeneca; Bayer; Biogen; Boehringer Ingelheim; cipla; Daiichi Pharmaceutical Co.; Ltd.; Genentech; Incyte; Kyowa Hakko Kirin; Medivation; Merck; MSD; Novartis; Pfizer; Roche; Sanofi Pasteur; Santen; Shire; Sunovion; Teva Pharmaceutical Industries Ltd; Theravance; Tocagen; UCB Pharma

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.

Medical Affairs’ Role in Patient Engagement: Collaboration with Internal and External Stakeholders and Activities along the Patient Journey

ID: 5457

Features:

Pages/Slides: 40

Published: Pre-2019

Delivery Format: Online PDF Document

STUDY OVERVIEW

KEY TOPICS

KEY METRICS

METHODOLOGY

RELATED RESEARCH

1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
69C3C5E1AEEE27BE48525810E00506D6D
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-medical-affairs-role-in-patient-engagement-collaboration-with-internal-and-external-stakeholders-and-activities-along-the-patient-journey?opendocument
18
19opendocument
2044.220.247.152
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB